NCT05479045 - A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions

Ovarian Cancer Stage IVOvarian Cancer Stage IIIOvarian Cancer Stage 3

Interventions

BIOLOGICAL

NY-ESO-1 Peptide vaccine

300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.

DRUG

Toripalimab-tpzi

240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine

Trial Locations (2)

20007

MedStar Georgetown University Hospital, Washington D.C.

07601

John Theurer Cancer Center, Hackensack